KE
Katie Ellias
OtherActiveManaging Director at T1D Fund
Boston, United StatesFounded 2015
23
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Katie Ellias.
Investment Thesis & Strategy
Katie Ellias, as Managing Director at T1D Fund, invests in various stages of biotech, healthcare, EdTech, health & hospital services, and health IT companies, with a focus on those related to type 1 diabetes.
Investment Activity
Deals per year over the last 5 years
1
20174
20185
20191
20201
2021Portfolio Companies
Selected investments from their portfolio of 23 companies
D
DiogenX
Biotech · Seed, 2021
V
Veralox Therapeutics
Biotech · Seed, 2020
i
i2o Therapeutics
Biotech · Seed, 2019
C
Capillary Biomedical
Healthcare · Seed, 2019
S
Sonoma BioTherapeutics
Biotech · Series B, 2019
E
Enthera
Biotech · Series A, 2019
K
Kriya Therapeutics
Biotech · Series B, 2019
I
IMTherapeutics
Biotech · Seed, 2018
I
Inversago Pharma
Biotech · Series A, 2018
T
Tetragenetics
Biotech · Seed, 2018
R
Repertoire Immune Medicines
Biotech · Series B, 2018
P
Provention Bio
Biotech · Series A, 2017
Frequently Asked Questions
Katie Ellias focuses on Seed stage investments.